Debby Vermeer-Kruijsen has a rich background in therapeutic antibody discovery and development. She has served different roles in Contract Research Biotech, including the role of General Manager at IPA Europe B.V. in Oss. Currently, she is active as an independent consultant in DVK Biotech to support early-stage biotech companies in business management. Debby is co-lead of the Biologics Workstream within Oncode Accelerator, active in building the most optimal infrastructure in the Netherlands to support early-stage biologics towards the clinic.

Jeanette Leusen is a full professor antibody therapy in the Center of Translational Immunology (CTI) of the University Medical Center in Utrecht. Her group focuses on the mechanism of action of natural and therapeutic antibodies, with a special interest in IgA as a novel class of antibody for the treatment of both malignant as infectious disease. She is heading the UMAB facility, founded in 2012, and is scientific founder of TigaTx, a spin-off company on engineered IgA as therapeutic antibody in oncology and 64Therapeutics, a spin-off company targeting CD64 in both auto-immune diseases and oncology. She is inventor of  > 10 patents. Jeanette is co-lead of the Biologics Workstream within Oncode Accelerator.